Journal article
Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A
eLife, Vol.9, e61119
10/19/2020
DOI: 10.7554/eLife.61119
PMCID: PMC7655101
PMID: 33074106
Abstract
Charcot-Marie-Tooth disease type 2A (CMT2A) is an untreatable childhood peripheral neuropathy caused by mutations of the mitochondrial fusion protein, mitofusin (MFN) 2. Here, pharmacological activation of endogenous normal mitofusins overcame dominant inhibitory effects of CMT2A mutants in reprogrammed human patient motor neurons, reversing hallmark mitochondrial stasis and fragmentation independent of causal
mutation. In mice expressing human
T105M, intermittent mitofusin activation with a small molecule, MiM111, normalized CMT2A neuromuscular dysfunction, reversed pre-treatment axon and skeletal myocyte atrophy, and enhanced axon regrowth by increasing mitochondrial transport within peripheral axons and promoting in vivo mitochondrial localization to neuromuscular junctional synapses. MiM111-treated
T105M mouse neurons exhibited accelerated primary outgrowth and greater post-axotomy regrowth, linked to enhanced mitochondrial motility. MiM111 is the first pre-clinical candidate for CMT2A.
Details
- Title: Subtitle
- Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A
- Creators
- Antonietta Franco - Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United StatesXiawei Dang - Department of Cardiology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, ChinaEmily K Walton - Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United StatesJoshua N Ho - Center for Regenerative Medicine, Washington University School of Medicine, St. Louis, United StatesBarbara Zablocka - Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, PolandCindy Ly - Department of Neurology, Washington University School of Medicine, St Louis, United StatesTimothy M Miller - Department of Neurology, Washington University School of Medicine, St Louis, United StatesRobert H Baloh - Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, United StatesMichael E Shy - Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, United StatesAndrew S Yoo - Center for Regenerative Medicine, Washington University School of Medicine, St. Louis, United StatesGerald W Dorn II - Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
- Resource Type
- Journal article
- Publication Details
- eLife, Vol.9, e61119
- DOI
- 10.7554/eLife.61119
- PMID
- 33074106
- PMCID
- PMC7655101
- NLM abbreviation
- Elife
- ISSN
- 2050-084X
- eISSN
- 2050-084X
- Publisher
- England
- Grant note
- R41 NS115184 / NINDS NIH HHS U54 NS053672 / NINDS NIH HHS 628906 / Muscular Dystrophy Association R35 HL135736 / NHLBI NIH HHS U54 NS065712 / NINDS NIH HHS R41 NS113642 / NINDS NIH HHS
- Language
- English
- Date published
- 10/19/2020
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Stead Family Department of Pediatrics; Iowa Neuroscience Institute
- Record Identifier
- 9984070835002771
Metrics
37 Record Views